Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Ultra-processed food consumption in obese adolescents is linked to insulin resistance and liver disease, stressing the need ...

The London-based biotechnology company said the non-dilutive funding will support its ongoing development of its lead gene therapy, GF-1002, for the treatment of metabolic associated steatohepatitis, ...

Professor Ramou Njie made this disclosure recently during her presentation as part of activities marking liver cancer ...

KOCHI: George (name changed), was 55-years-old when he was diagnosed with fatty liver. Since he was a teetotaller, he did not ...

Symptoms that are sometimes diagnosed as part of dementia might actually be related to a treatable liver condition, according to a recent study. Up to 13% of patients believed to have dementia are ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for ...

The study first used laboratory models of pulmonary TB to examine the changes happening within the liver during the early ...

A study has shown that tuberculosis disrupts glucose metabolism in the liver, potentially leading to diseases like diabetes.

Scientists from the University of Leicester have discovered that tuberculosis disrupts glucose metabolism in the body.

Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, ...